Ibrutinib and Lenalidomide Combination in Leukemia Carries High Cardiac Toxicity Risk
A phase 1 clinical trial revealed that combining ibrutinib with lenalidomide in relapsed chronic lymphocytic leukemia produced durable disease control ...
A phase 1 clinical trial revealed that combining ibrutinib with lenalidomide in relapsed chronic lymphocytic leukemia produced durable disease control ...
A secondary psychometric analysis demonstrated that the PROMIS Medication Adherence Scale provides reliable self-reported monitoring for patients taking oral anticancer ...
A targeted literature review of multiple myeloma across the Middle East and North Africa shows that patients are diagnosed at ...
A detailed case report shows how bone marrow analysis and genetic testing can distinguish rare immunoglobulin M multiple myeloma from ...
A multi-omic analysis reveals that coordinated NF-κB-driven inflammation across bone marrow immune and plasma cells impairs daratumumab and lenalidomide response ...
Researchers have identified the Notch downstream effector NFIL3 as an independent prognostic marker and therapeutic vulnerability whose inhibition with Raddeanin ...
A clinical report documents an unexpected seven-year hematologic response to lenalidomide rechallenge in a patient with therapy-related myelodysplastic neoplasm harboring ...
A multicentre phase II platform trial protocol establishes sequential testing of zanubrutinib monotherapy and combinations for relapsed primary central nervous ...
Clinical case analyses reveal that psoriasis flares improved despite continuous lenalidomide treatment, challenging assumptions that drug-induced TH17 reprogramming directly drives ...
A prospective clinical trial found response-adapted lenalidomide and dexamethasone intensification before transplantation did not surpass historical complete response benchmarks.
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine